• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DNA 解旋酶基因的表达与乳腺癌同源重组缺陷相关。

Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.

机构信息

Department of Pathology, Peking University Cancer Hospital, Beijing, China.

Department of Breast Surgery, Peking University People's Hospital, Beijing, China.

出版信息

Comput Math Methods Med. 2022 Jul 9;2022:5508301. doi: 10.1155/2022/5508301. eCollection 2022.

DOI:10.1155/2022/5508301
PMID:35855837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9288330/
Abstract

Homologous recombination deficiency which is currently measured by the homologous recombination deficiency (HRD) score including score of telomeric allelic imbalance (TAI), large-scale transition (LST), and loss of heterozygosity (LOH) is highly related with sensitivity to platinum-containing drug and PARP inhibitors. DNA helicases are essential components for the homologous recombination repair process in which DNA helicases unwind double-strand DNA utilizing ATP hydrolysis. In our study, the correlation between the expression of DNA helicase genes and HRD score in breast cancer was analyzed. The overexpression in half of the DNA helicase genes was found to be highly correlated with a high HRD score both in BRCA-mutated and BRCA wild-type breast cancer. Moreover, HRD score can be predicted by a linear function contributed by five DNA helicase genes. In conclusion, our study revealed a close relation between the overexpression of certain DNA helicase genes and the deficiency of homologous recombination repair in breast cancer.

摘要

同源重组缺陷（HRD）评分目前可通过包括端粒等位基因不平衡（TAI）、大片段转移（LST）和杂合性丢失（LOH）评分来衡量，与铂类药物和 PARP 抑制剂的敏感性高度相关。DNA 解旋酶是同源重组修复过程中的必需组成部分，该过程中 DNA 解旋酶利用 ATP 水解解开双链 DNA。在本研究中，分析了 DNA 解旋酶基因的表达与乳腺癌 HRD 评分之间的相关性。结果发现，在 BRCA 突变型和 BRCA 野生型乳腺癌中，有一半的 DNA 解旋酶基因的过表达与高 HRD 评分高度相关。此外，HRD 评分可以通过由 5 个 DNA 解旋酶基因组成的线性函数来预测。综上所述，本研究揭示了某些 DNA 解旋酶基因的过表达与乳腺癌同源重组修复缺陷之间的密切关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/5613853bb250/CMMM2022-5508301.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/a05e079e5e37/CMMM2022-5508301.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/8453b7214211/CMMM2022-5508301.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/ddaf38a310c5/CMMM2022-5508301.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/ce89e02f45ef/CMMM2022-5508301.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/5613853bb250/CMMM2022-5508301.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/a05e079e5e37/CMMM2022-5508301.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/8453b7214211/CMMM2022-5508301.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/ddaf38a310c5/CMMM2022-5508301.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/ce89e02f45ef/CMMM2022-5508301.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deee/9288330/5613853bb250/CMMM2022-5508301.005.jpg

相似文献

1
Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.DNA 解旋酶基因的表达与乳腺癌同源重组缺陷相关。
Comput Math Methods Med. 2022 Jul 9;2022:5508301. doi: 10.1155/2022/5508301. eCollection 2022.
2
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.乳腺癌亚型中BRCA1/2缺陷与预测DNA损伤修复缺陷的基因组评分之间的关联。
Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
3
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.同源重组缺陷（HRD）评分可预测三阴性乳腺癌患者对含铂新辅助化疗的反应。
Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.
4
Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.光学基因组图谱绘制：整合结构变异以精确计算同源重组缺陷评分。
Genes (Basel). 2023 Aug 25;14(9):1683. doi: 10.3390/genes14091683.
5
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.同源重组缺陷与微卫星不稳定性呈负相关，可在大多数癌症类型中识别出免疫“冷”肿瘤。
J Pathol Clin Res. 2022 Jul;8(4):371-382. doi: 10.1002/cjp2.271. Epub 2022 Apr 5.
6
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.基因组疤痕作为乳腺癌和卵巢癌中同源重组缺陷及药物反应的生物标志物
Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
7
Homologous recombination deficiency and ovarian cancer.同源重组缺陷与卵巢癌
Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9.
8
Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.从 Oncomine Comprehensive Assay Plus 预测同源重组缺陷并与 SOPHiA DDM HRD Solution 相关联。
PLoS One. 2024 Mar 25;19(3):e0298128. doi: 10.1371/journal.pone.0298128. eCollection 2024.
9
Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.基于单核苷酸多态性的基因组不稳定性检测与基于下一代测序的同源重组缺陷检测的一致性。
BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z.
10
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.破解同源重组缺陷密码：如何识别对PARP抑制剂有反应的患者
Eur J Cancer. 2022 May;166:87-99. doi: 10.1016/j.ejca.2022.01.037. Epub 2022 Mar 10.

引用本文的文献

1
Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of Expression Status.无论 ER 表达状态如何，在乳腺癌中表达与独特的临床病理和基因组特征相关。
Int J Mol Sci. 2022 Sep 29;23(19):11468. doi: 10.3390/ijms231911468.

本文引用的文献

1
A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.基于雄激素受体通路基因的机器学习方法对两种特定乳腺癌亚型的鉴别。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211027900. doi: 10.1177/15330338211027900.
2
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores.基于通路评分对 ER 阳性和 HER2 阴性乳腺癌中 PR 阳性和 PR 阴性亚型进行分类。
BMC Med Res Methodol. 2021 May 22;21(1):108. doi: 10.1186/s12874-021-01297-8.
3
A Histone Acetylation Modulator Gene Signature for Classification and Prognosis of Breast Cancer.
一种用于乳腺癌分类和预后的组蛋白乙酰化调节剂基因特征。
Curr Oncol. 2021 Feb 17;28(1):928-939. doi: 10.3390/curroncol28010091.
4
Pharmacological targeting of differential DNA repair, radio-sensitizes WRN-deficient cancer cells in vitro and in vivo.靶向差异 DNA 修复的药理学方法可在体外和体内使 WRN 缺陷型癌细胞对放射增敏。
Biochem Pharmacol. 2021 Apr;186:114450. doi: 10.1016/j.bcp.2021.114450. Epub 2021 Feb 8.
5
Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer o and .小分子靶向 RECQL5 功能，选择性杀伤乳腺癌 o 和 。
J Med Chem. 2021 Feb 11;64(3):1524-1544. doi: 10.1021/acs.jmedchem.0c01692. Epub 2021 Feb 2.
6
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.靶向自噬可逆转同源重组修复功能正常的乳腺癌对 PARP 抑制的新生耐药性。
Br J Cancer. 2021 Mar;124(7):1260-1274. doi: 10.1038/s41416-020-01238-0. Epub 2021 Jan 21.
7
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.尼拉帕利联合卡铂和紫杉醇治疗 BRCA 突变型晚期乳腺癌（BROCADE3）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27.
8
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.他拉唑帕尼与化疗治疗胚系BRCA1/2突变的HER2阴性晚期乳腺癌患者：EMBRACA试验的最终总生存结果
Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20.
9
The Regulation of Homologous Recombination by Helicases.解旋酶对同源重组的调控。
Genes (Basel). 2020 May 1;11(5):498. doi: 10.3390/genes11050498.
10
RECQL5: Another DNA helicase potentially involved in hereditary breast cancer susceptibility.RECQL5：另一种可能与遗传性乳腺癌易感性相关的 DNA 解旋酶。
Hum Mutat. 2019 May;40(5):566-577. doi: 10.1002/humu.23732. Epub 2019 Mar 13.